In this Issue
- New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics
- MAHA Report Slams Psychiatric Drug Use Among America’s Youth
- Beckley Psytech’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD
- and more…
***
New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics
Earlier this month, a manuscript by Zaki et al. (2025) looked at the long-term safety and efficacy of esketamine nasal spray (Spravato) in treatment-resistant depression (TRD). It provides an unprecedented look at how the product is used over the medium and long term, such as average treatment duration, reasons for discontinuation, and outcomes.
The data is derived from the open-label long-term extension study conducted by the drug’s manufacturer, Janssen (part of Johnson & Johnson), between June 2016 and December 2022 (SUSTAIN-3). It represents 1,148 patients who participated in the company’s Phase 3 studies of the drug, who were exposed to Spravato for a cumulative 3,777 patient-years.
Headline findings include a mean exposure to Spravato of 42.9 months, i.e. just over three and a half years. That is substantial, especially given the context of in-person clinic visits and the fact that much of the long-term extension study took place during the peak of the COVID-19 pandemic.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
